Guillaume Berton, Bochra Sedaki, Erwann Collomb, Sami Benachour, Michael Loschi, Bilal Mohty, Colombe Saillard, Yosr Hicheri, Camille Rouzaud, Valerio Maisano, Ferdinand Villetard, Evelyne D 'Incan Corda, Aude Charbonnier, Jerome Rey, Marie-Anne Hospital, Antoine Ittel, Norman Abbou, Raphaelle Fanciullino, Bérengère Dadone-Montaudié, Norbert Vey, Geoffroy Venton, Thomas Cluzeau, Anne-Sophie Alary, Sylvain Garciaz
Mutations in spliceosome genes (SRSF2, SF3B1, U2AF1, ZRSR2) correlate with inferior outcomes in patients treated with intensive chemotherapy for Acute Myeloid Leukemia. However, their prognostic impact in patients treated with less intensive protocols is not well known. This study aimed to evaluate the impact of Spliceosome mutations in patients treated with Venetoclax and Azacitidine for newly diagnosed AML. 117 patients treated in 3 different hospitals were included in the analysis. 34 harbored a mutation in at least one of the spliceosome genes (splice-mut cohort)...
April 15, 2024: Leukemia Research